lipoxin


Also found in: Wikipedia.

lipoxin

(li-pok'sin)
Any of a group of eicosanoids formed by the action of phospholipases on cell membrane phospholipids. Some lipoxins have anti-inflammatory effects, but some promote inflammation and hypersensitivity reactions. See: leukotriene; prostaglandin
References in periodicals archive ?
Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection.
Tambien posee acciones antiinflamatorias cuyo mecanismo involucra la sintesis de lipoxinas o ATL (Aspirin-Triggered Lipoxin).
Background: Lipoxin A4 (LXA4) can alleviate lipopolysaccharide (LPS)-induced acute lung injury (ALI) and acute respiratory distress syndrome through promoting epithelial sodium channel (ENaC) expression in lung epithelial cells.
Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection.
Xu et al., "Lipoxin A4 reduces inflammation through formyl peptide receptor 2/p38 MAPK signaling pathway in subarachnoid hemorrhage rats," Stroke, vol.
Sun, "Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-[kappa]B/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation," Neuroscience, vol.
Muljadi et al., "Amnion epithelial cells promote lung repair via lipoxin A4," Stem Cells Translational Medicine, vol.
Interestingly, opposite effects were seen upon treatment with the eicosanoid lipoxin A4, which reduced adipose tissue inflammation as evidenced by diminished tissue expression of proinflammatory cytokines and higher macrophage polarization to the anti-inflammatory M2 profile [164].
RvD1 exerts its biological functions through interaction with G-protein-coupled receptor 32 (GPR32) or lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2).
These include Lipoxin A4, eosinophils and protectin D1.
The NSAIDs exert therapeutic effects by inhibition of the cyclooxygenase (COX) enzymes, which block the conversion of arachidonic acid to proinflammatory prostaglandin mediators, and by blocking anti-inflammatory mediators such as lipoxin. Meloxicam is an NSAID that is an enolic acid derivative and a COX-2 preferential inhibitor in the species studied.
Lysophospholipid-derived lipid mediators (LPA and PAF) and PUFA-derived anti-inflammatory lipid mediators (lipoxin, resolvin and protectin).